M.D. Anderson Cancer Center: Urologic Neoplasms trials

The registry lists 10 Urologic Neoplasms studies with M.D. Anderson Cancer Center as lead sponsor. 1 are open to participants now and 2 have results posted.

Early Phase 1 2Phase 1 5Phase 2 1Phase 4 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary MetastasesRecruitingNCT03093909Phase 1
• Neuromuscular Blockade on Shoulder Pain of ElderlyCompletedNCT03210376Phase 4Results posted
• Investigation of Sugammadex in Outpatient Urological ProceduresCompletedNCT03138967Phase 4Results posted
• Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell CarcinomaActive, not recruitingNCT03541902Phase 2
• Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney CancerCompletedNCT03473730Early Phase 1
• Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NTActive, not recruitingNCT03435952Phase 1
• Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid TumorsTerminatedNCT03420963Phase 1
• Oral Supplementation to Enhance Recovery Pilot StudyCompletedNCT03204266Early Phase 1
• Lenvatinib and Capecitabine in Patients With Advanced MalignanciesWithdrawnNCT02915172Phase 1
• Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign DiseaseTerminatedNCT01552434Phase 1